In­cyte hires Janssen ex­ec as CSO Hu­ber moves to Third Rock; Syn­thorx set terms for $100M IPO

→ Ahead of an FDA de­ci­sion on its key drug Jakafi’s use in graft vs. host dis­ease, In­cyte $IN­CY has lost its chief sci­en­tif­ic of­fi­cer Reid Hu­ber to promi­nent health­care ven­ture firm Third Rock, but is bring­ing in Janssen’s Dashyant Dhanak to fill the gap.

Dhanak will need to get his act to­geth­er be­fore the up­com­ing Amer­i­can So­ci­ety of Hema­tol­ogy (ASH) con­fer­ence slat­ed for this week­end, where In­cyte is mak­ing mul­ti­ple da­ta pre­sen­ta­tions, in­clud­ing up­dat­ed da­ta for Jakafi in com­bi­na­tion with its PI3K-delta in­hibitor IN­CB50465 in pa­tients with myelofi­bro­sis. This com­bi­na­tion is ex­pect­ed to play a crit­i­cal role in ex­pand­ing the Jakafi fran­chise in myelo­pro­lif­er­a­tive neo­plasms, a group of rare dis­or­ders of the bone mar­row that cause an in­crease in the num­ber of blood cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER